PL2257624T3 - Sposoby i kompozycje - Google Patents

Sposoby i kompozycje

Info

Publication number
PL2257624T3
PL2257624T3 PL09708496T PL09708496T PL2257624T3 PL 2257624 T3 PL2257624 T3 PL 2257624T3 PL 09708496 T PL09708496 T PL 09708496T PL 09708496 T PL09708496 T PL 09708496T PL 2257624 T3 PL2257624 T3 PL 2257624T3
Authority
PL
Poland
Prior art keywords
polypeptide
methods
compositions
relates
attached
Prior art date
Application number
PL09708496T
Other languages
English (en)
Inventor
Gregory Winter
Christian Heinis
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40792924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2257624(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0802079.4A external-priority patent/GB0802079D0/en
Priority claimed from GB0818399A external-priority patent/GB0818399D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of PL2257624T3 publication Critical patent/PL2257624T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
PL09708496T 2008-02-05 2009-02-04 Sposoby i kompozycje PL2257624T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0802079.4A GB0802079D0 (en) 2008-02-05 2008-02-05 Method and compositions
GB0818399A GB0818399D0 (en) 2008-10-08 2008-10-08 Methods and compositions
EP09708496A EP2257624B9 (en) 2008-02-05 2009-02-04 Methods and compositions
PCT/GB2009/000301 WO2009098450A2 (en) 2008-02-05 2009-02-04 Methods and compositions

Publications (1)

Publication Number Publication Date
PL2257624T3 true PL2257624T3 (pl) 2012-09-28

Family

ID=40792924

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09708496T PL2257624T3 (pl) 2008-02-05 2009-02-04 Sposoby i kompozycje

Country Status (11)

Country Link
US (3) US8680022B2 (pl)
EP (5) EP2653544A1 (pl)
JP (2) JP6074574B2 (pl)
AT (1) ATE555200T1 (pl)
AU (1) AU2009211253B2 (pl)
CA (1) CA2714477C (pl)
DK (2) DK2474613T3 (pl)
ES (2) ES2383191T3 (pl)
PL (1) PL2257624T3 (pl)
PT (1) PT2257624E (pl)
WO (1) WO2009098450A2 (pl)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0913775D0 (en) * 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
GB0914110D0 (en) * 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
JP2013518807A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
JP2013518558A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 構造化されたペプチドプロセシング
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
CN103403160A (zh) * 2010-08-13 2013-11-20 G·克里斯蒂安森 修饰肽的展示
GB201013980D0 (en) 2010-08-20 2010-10-06 Ecole Polytech Bicyclic uPA inhibitors
RU2657440C2 (ru) 2011-06-30 2018-06-13 Джензим Корпорейшн Ингибиторы т-клеточной активации
JP6254527B2 (ja) * 2011-10-07 2017-12-27 バイサイクル・セラピューティクス・リミテッド 構造化ポリペプチドの特異性のモジュレーション
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
JP2015508638A (ja) 2012-02-03 2015-03-23 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ ファージディスプレイを用いてペプチド誘導体ライブラリーを定量化するための方法
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
AU2013260123A1 (en) 2012-05-10 2014-11-13 Massachusetts Institute Of Technology Agents for influenza neutralization
AU2013299986B2 (en) 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
EP3456734B1 (en) 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
AU2013350802B2 (en) * 2012-11-30 2016-07-14 Novartis Ag Methods for making conjugates from disulfide-containing proteins
GB201306623D0 (en) * 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
JP6474404B2 (ja) 2013-08-14 2019-02-27 ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用
WO2015063465A2 (en) * 2013-10-28 2015-05-07 Bicycle Therapeutics Limited Novel polypeptides
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
WO2015166036A1 (en) 2014-05-02 2015-11-05 Morphosys Ag Peptide libraries
GB201413086D0 (en) 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
EP3209819B1 (en) 2014-10-22 2024-02-14 The Governors Of The University Of Alberta Genetic encoding of chemical post-translational modification for phage-displayed libraries
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
KR101693665B1 (ko) * 2014-11-13 2017-01-06 목포해양대학교 산학협력단 설치와 철거가 용이한 구조를 가지는 기초의 세굴방지장치 및 이를 이용한 기초의 세굴방지방법
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
JP6609099B2 (ja) * 2014-12-10 2019-11-20 キヤノン株式会社 放射線検出装置、及び放射線検出シート
DK3237614T3 (da) 2014-12-22 2019-09-09 Lanthiopep Bv Nye fremgangsmåder til fremvisning af cyklisk peptider på overfladen af bakteriofagpartikler
WO2016170101A1 (en) * 2015-04-23 2016-10-27 F. Hoffmann-La Roche Ag Cow antibody scaffold polypeptide method and composition
JP2015214568A (ja) * 2015-07-13 2015-12-03 バイスクル・セラピューティクス・リミテッド 多重特異性ペプチド
DK3417058T3 (da) 2016-02-16 2021-11-15 Res Found Dev Sortase-modificerede molekyler og anvendelser deraf
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
CN109312324B (zh) * 2016-06-07 2022-08-16 株式会社钟化 核糖体展示复合体及其制造方法
CA3043464A1 (en) 2016-11-09 2018-05-17 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
US10913773B2 (en) 2016-11-22 2021-02-09 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
WO2018096365A1 (en) 2016-11-27 2018-05-31 Bicyclerd Limited Methods for treating cancer
CA3046171A1 (en) 2016-12-06 2018-06-14 Stichting Voor De Technische Wetenschappen Multicyclic peptides and methods for their preparation
EP3559018A1 (en) * 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
MX2019007367A (es) * 2016-12-23 2020-01-27 Bicycletx Ltd Ligandos de peptido para enlace a mt1-mmp.
ES2985986T3 (es) 2017-01-06 2024-11-08 Bicyclerd Ltd Conjugado biciclo para tratar el cáncer
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
EP3577258B1 (en) 2017-01-31 2024-11-27 48Hour Discovery Inc. Display of molecules on silently genetically encoded nanoscale carriers for determining synergistic molecular interactions
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
WO2018224636A1 (en) 2017-06-09 2018-12-13 Vib Vzw Glutamine dehydrogenase inhibitors for use in muscle regeneration
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
CA3099077A1 (en) 2017-07-13 2019-01-17 Michael David FORREST Therapeutic modulators of the reverse mode of atp synthase
CA3069998A1 (en) 2017-07-17 2019-01-24 Vib Vzw Targeting synaptogyrin-3 in tauopathy treatment
JP7670481B2 (ja) * 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
EP3701259A1 (en) 2017-10-26 2020-09-02 VIB vzw Podoplanin positive macrophages
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
CA3095582A1 (en) 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
GB201808835D0 (en) 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
GB201810325D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810320D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810316D0 (en) * 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810329D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
US12391939B2 (en) 2018-07-23 2025-08-19 The Governors Of The University Of Alberta Genetically-encoded bicyclic peptide libraries
WO2020023620A1 (en) * 2018-07-25 2020-01-30 Trustees Of Boston College Methods and compositions of chemically modified phage libraries
US11655468B2 (en) 2018-07-25 2023-05-23 The Trustees Of Boston College Methods and compositions of chemically modified phage libraries
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
GB201819659D0 (en) 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
SG11202106081YA (en) * 2018-12-13 2021-07-29 Bicycletx Ltd Bicyclic peptide ligands specific for mt1-mmp
GB201820320D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
EP3897849A1 (en) * 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
GB201900525D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
GB201900527D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020178574A1 (en) 2019-03-04 2020-09-10 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
KR20220007098A (ko) 2019-05-09 2022-01-18 바이사이클티엑스 리미티드 Ox40에 특이적인 이환식 펩티드 리간드
EP3976067A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4010352B1 (en) 2019-08-07 2023-10-18 Gyros Protein Technologies AB A method for modification of peptides immobilized on a solid support by traceless reductively cleavable linker molecules
US20220275053A1 (en) 2019-08-13 2022-09-01 Bicycletx Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
SI4464721T1 (sl) 2019-10-03 2025-08-29 Bicycletx Limited Heterotandemski biciklični peptidni kompleksi
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
CN114760988A (zh) 2019-11-27 2022-07-15 拜斯科技术开发有限公司 对EphA2具有特异性的双环肽配体和其用途
GB201918558D0 (en) * 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918559D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918557D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
EP4077349A1 (en) 2019-12-16 2022-10-26 BicycleTX Limited Bicyclic peptide ligands specific for il-17
CN110907422B (zh) * 2019-12-16 2021-07-06 吉林大学 基于Ti3C2的凝血酶适体传感器及其制备方法
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
WO2021205161A1 (en) 2020-04-06 2021-10-14 Bicycletx Limited Bicyclic peptide ligands specific for tslp
WO2021220011A1 (en) 2020-05-01 2021-11-04 Bicycletx Limited Anti-infective bicyclic peptide conjugates
CN116018349A (zh) 2020-05-15 2023-04-25 拜斯科技术开发有限公司 抗感染的双环肽配体
EP4165414A1 (en) 2020-06-12 2023-04-19 BicycleTX Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
CN111893577B (zh) * 2020-08-06 2022-03-22 厦门大学 基于4-羟基-2,6-二氟-1,3,5-苯三腈构建噬菌体展示环肽库的方法
WO2022038158A1 (en) 2020-08-17 2022-02-24 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
GB202016331D0 (en) 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
CN116802190A (zh) 2020-11-13 2023-09-22 拜斯科技术开发有限公司 特异于转铁蛋白受体1（TfR1）的双环肽配体
EP4274843A1 (en) 2021-01-08 2023-11-15 BicycleTx Limited Anti-infective bicyclic peptide ligands
JP2024504068A (ja) * 2021-01-08 2024-01-30 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
US20240108737A1 (en) 2021-01-08 2024-04-04 Bicycletx Limited Anti-infective bicyclic peptide ligands
AU2022206394A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Bicyclic peptide ligands specific for nk cells
JP2024503642A (ja) 2021-01-08 2024-01-26 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
CA3207009A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
CA3206529A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Heterotandem bicyclic peptide complexes
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
US20250325469A1 (en) 2021-01-24 2025-10-23 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
CN117241804A (zh) 2021-02-17 2023-12-15 非营利性组织佛兰芒综合大学生物技术研究所 在癌症治疗中slc4a4的抑制
JP2024509996A (ja) 2021-03-19 2024-03-05 バイスクルテクス・リミテッド Ｔｒｅｍ２に特異的な二環式ペプチドリガンド
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
US12150998B2 (en) 2021-04-20 2024-11-26 Bicycletx Limited Bicyclic peptide ligands specific for P-selectin
EP4380691A1 (en) 2021-08-06 2024-06-12 Institut Régional du Cancer de Montpellier (ICM) Methods for the treatment of cancer
WO2023031623A2 (en) 2021-09-03 2023-03-09 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
AU2022357561A1 (en) 2021-10-01 2024-04-18 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
GB202114279D0 (en) 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB202114282D0 (en) 2021-10-06 2021-11-17 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
GB202116263D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Anti-infective bicyclic peptide ligands
GB202116266D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Novel use
CN114166924B (zh) * 2021-12-03 2024-11-22 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途
EP4469081A1 (en) 2022-01-24 2024-12-04 Cambridge Enterprise Limited Tau therapy
GB202206431D0 (en) 2022-05-03 2022-06-15 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
WO2024009108A1 (en) 2022-07-07 2024-01-11 Bicycletx Limited Anti-infective bicyclic peptide ligands
WO2024160756A1 (en) 2023-01-30 2024-08-08 Vib Vzw Suppressors of tauopathies
IL322909A (en) 2023-03-09 2025-10-01 Bicycletx Ltd Synthesis of bicyclic toxin conjugates and their intermediates
WO2024248860A1 (en) 2023-06-01 2024-12-05 Bicycletx Limited Bicyclic peptide ligands specific for epha2 and uses thereof
EP4719481A1 (en) 2023-06-01 2026-04-08 BicycleTx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2024248859A1 (en) 2023-06-01 2024-12-05 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
EP4719480A1 (en) 2023-06-01 2026-04-08 BicycleTx Limited Bicyclic peptide ligands specific for epha2 and uses thereof
WO2024252336A1 (en) 2023-06-07 2024-12-12 Peptidream Inc. Peptide compositions targeting glypican-3 and uses thereof
JP2026525826A (ja) 2023-06-23 2026-08-04 バイスクルテクス・リミテッド Ｎｋ細胞に特異的な二環式ペプチドリガンド
GB202312685D0 (en) 2023-08-18 2023-10-04 Bicycletx Ltd Computer implemented method
CN122094701A (zh) 2023-09-01 2026-05-26 拜斯科技术开发有限公司 Tlr3结合双环肽配体
GB202313403D0 (en) 2023-09-01 2023-10-18 Bicycletx Ltd Polypeptide screening
EP4777136A1 (en) 2023-09-13 2026-07-22 BicycleTx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2025067347A1 (zh) * 2023-09-28 2025-04-03 深圳湾实验室坪山生物医药研发转化中心 噬菌体颗粒复合物、其制备方法及其用途
WO2025085724A1 (en) * 2023-10-18 2025-04-24 University Of Utah Research Foundation An enzymatic method for synthesis of interpeptide thioether crosslinks
GB202316970D0 (en) 2023-11-06 2023-12-20 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
WO2025125648A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Bicyclic peptide complex for use in treating cancer
WO2025125809A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2025125652A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Combination therapy for use in treating cancer
WO2025191096A1 (en) 2024-03-14 2025-09-18 Bicycletx Limited Bicyclic peptide
GB202410566D0 (en) 2024-07-19 2024-09-04 Bicycletx Ltd Computer implemented method
WO2026159271A1 (en) 2025-01-24 2026-07-30 Bicycletx Limited Bicyclic peptide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313509D0 (en) * 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1998036743A1 (en) 1997-02-21 1998-08-27 Cypros Pharmaceutical Corporation Neuroprotective poly-guanidino compounds which block presynaptic n and p/q calcium channels
CA2347973C (en) * 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
EP1224327A4 (en) 1999-09-29 2004-09-08 Xenoport Inc COMPOSITIONS ON GENETICALLY REPLICABLE PRODUCTS AND METHODS FOR THEIR USE
EP1385984A4 (en) 2001-03-21 2007-06-13 Xenoport Inc COMPOUND PRESENTED ON AN ICOSAEDRIC PHAGE AND METHOD OF USE THEREOF
EP1504111A4 (en) 2002-04-19 2005-11-23 California Inst Of Techn LIBRARY OF MOLECULES OF NUCLEIC ACIDS AND PEPTIDES IN WHICH THE PEPTIDES CONTAIN NON-NATURAL AMINO ACID RESIDUES AND METHODS FOR THEIR PRODUCTION
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
ES2428869T3 (es) * 2005-01-24 2013-11-12 Pepscan Systems B.V. Compuestos de unión, compuestos inmunógenos y peptidomiméticos
WO2006095345A2 (en) 2005-03-08 2006-09-14 Ramot At Tel-Aviv University Ltd. Targeted drug-carrying bacteriophages
US20100322945A1 (en) * 2006-07-26 2010-12-23 Peter Timmerman Immunogenic compounds and protein mimics
WO2008074895A1 (en) * 2006-12-21 2008-06-26 Cytos Biotechnology Ag Circular ccr5 peptide conjugates and uses thereof

Also Published As

Publication number Publication date
EP2653543A1 (en) 2013-10-23
US20140187757A1 (en) 2014-07-03
EP2257624B9 (en) 2012-08-01
ATE555200T1 (de) 2012-05-15
ES2383191T3 (es) 2012-06-19
JP6074574B2 (ja) 2017-02-08
AU2009211253A1 (en) 2009-08-13
DK2474613T3 (da) 2014-10-06
US20150166988A1 (en) 2015-06-18
EP2474613B2 (en) 2022-02-16
CA2714477A1 (en) 2009-08-13
ES2383191T9 (es) 2012-10-16
DK2257624T3 (da) 2012-05-29
EP2653545A1 (en) 2013-10-23
JP2015109856A (ja) 2015-06-18
PT2257624E (pt) 2012-05-29
US20100317547A1 (en) 2010-12-16
AU2009211253B2 (en) 2014-11-06
WO2009098450A3 (en) 2009-10-29
US9670484B2 (en) 2017-06-06
ES2509959T5 (en) 2024-12-19
EP2653544A1 (en) 2013-10-23
JP2011514803A (ja) 2011-05-12
WO2009098450A2 (en) 2009-08-13
EP2474613B1 (en) 2014-07-16
EP2474613A1 (en) 2012-07-11
US9657288B2 (en) 2017-05-23
DK2257624T5 (da) 2012-09-10
EP2257624A2 (en) 2010-12-08
CA2714477C (en) 2018-10-16
JP6075658B2 (ja) 2017-02-08
US8680022B2 (en) 2014-03-25
ES2509959T3 (es) 2014-10-20
EP2257624B1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
DK2257624T5 (da) Fremgangsmåder og sammensætninger
MX2009007695A (es) Compuestos complejos de carbohidrato de hierro.
WO2010006173A3 (en) Mineral amino acid polysaccharide complex
UA93424C2 (en) Preparation of azoxystrobin
MX2008016039A (es) Preparacion de glucano.
WO2011060242A3 (en) Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
WO2010039900A3 (en) Non-human mammals for the production of chimeric antibodies
EP4345164A3 (en) Genetic engineering of non-human animals for the production of chimeric antibodies
WO2012100176A3 (en) Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
WO2009137455A3 (en) Cure accelerators for anaerobic curable compositions
WO2012045022A3 (en) Metabolic engineering of clostridium tyrobutyricum for butanol production
IL197838A0 (en) High-purity large scale preparation of stannsoporfin
WO2009137444A3 (en) Cure accelerators for anaerobic curable compositions
GB201315932D0 (en) Catalyst compositions containing transition metal complexes with thiolate ligands
MY151180A (en) Electrocoating composition comprising a crater control additive
GB2497841A (en) Subsea hydrocarbon production system
MX2020008073A (es) Biocatalizador y metodos para sintetizar conjugados mezclados de disulfuro de compuestos de tienopiridina.
WO2008075966A3 (en) Synthesis of a radiofluorinated peptide using photolabile protecting groups
WO2008034062A3 (en) Method for making cobalt nanomaterials
IL211266A0 (en) Improved process for the addition of thiolates to alfa, beta-unsaturated carbonyl or sulfonyl compounds
WO2011146439A3 (en) Identifying antifungal agents that inhibit iaa or a yap family member
WO2011023791A3 (de) Verfahren zur herstellung von organoaluminiumverbindungen und deren verwendung
WO2006087613A3 (en) Stable oral benzimidazole compositions prepared by non-aqueous layering process
MY141734A (en) Methods for producing quinazoline alkaloids